Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MYCN is a proto-oncogene being investigated as a therapeutic target and gene therapy candidate for cardiac regeneration. In the context of myocardial infarction (MI), MYCN is delivered via cardiomyocyte-specific adeno-associated viral (AAV) vectors to induce cell cycle activity in mature cardiomyocytes, which typically have limited regenerative capacity. Preclinical studies in mature mice have demonstrated that overexpression of the Mycn isoform promotes cardiomyocyte mitosis, angiogenesis, and fibroblast activation. This therapeutic approach has shown potential in protecting cardiac function by preventing the significant decline in left ventricular ejection fraction (LVEF) following myocardial injury.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on MYCN.